ReviewMolecular endocrinology (Baltimore, Md.)2016
The Estrogen Receptor α-Cistrome Beyond Breast Cancer.
Review in Molecular endocrinology (Baltimore, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Estrogen Receptor Chromatin Profiling by CUT&RUN.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The Estrogen Receptor α Cistrome in Human Endometrium and Epithelial Organoids.Endocrinology · 2022Article
- Cooperative interaction between ERα and the EMT-inducer ZEB1 reprograms breast cancer cells for bone metastasis.Nature communications · 2022Article
- Gene X environment: the cellular environment governs the transcriptional response to environmental chemicals.Human genomics · 2020Article
- The Impact of Skeletal Muscle ERα on Mitochondrial Function and Metabolic Health.Endocrinology · 2020Review
- Signatures of sex: Sex differences in gene expression in the vertebrate brain.Wiley interdisciplinary reviews. Developmental biology · 2020Review
- Article
- Insights into breast cancer phenotying through molecular omics approaches and therapy response.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- The impact of ERα action on muscle metabolism and insulin sensitivity - Strong enough for a man, made for a woman.Molecular metabolism · 2018Review
- Multiplex Enhancer Interference Reveals Collaborative Control of Gene Regulation by Estrogen Receptor α-Bound Enhancers.Cell systems · 2017Article
- Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although many tissues express estrogen receptor (ER)α, most studies focus on breast cancer where ERα occupies just a small fraction of its total repertoire of potential DNA-binding sites, based on sequence. This raises the question: Can ERα occupy these other potential binding sites in a different context? Ligands, splice variants, posttranslational modifications, and acquired mutations of ERα affect its conformation, which may alter chromatin interactions. To date, literature describes the DNA-binding sites of ERα (the ERα cistrome) in breast, endometrium, liver, and bone, in which the receptor mainly binds to enhancers. Chromosomal boundaries provide distinct areas for dynamic gene regulation between tissues, where the usage of enhancers deviates. Interactions of ERα with enhancers and its transcriptional complex depend on the proteome, which differs per cell type. This review discusses the biological variables that influence ERα cistromics, using reports from human specimens, cell lines, and mouse tissues, to assess whether ERα genomics in breast cancer can be translated to other tissue types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.